Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exicure, Inc.
  6. News
  7. Summary
    XCUR   US30205M1018

EXICURE, INC.

(XCUR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exicure : to Present at the Benzinga Healthcare Small Cap Conference

09/23/2021 | 07:02am EST

Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will present at the Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021, at 3:20 PM ET.

Exicure management will be available for one-on-one meetings to be held throughout the conference. Investors can register to receive a free spectator pass for the event here.

The conference live stream will be available here. Replays of the presentation will be available on Exicure’s website following the presentation.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. www.exicuretx.com


ę Business Wire 2021
All news about EXICURE, INC.
12/07ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Exicure, Inc. Investors with Losses to Inqu..
PR
11/23Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clini..
MT
11/22EXICURE ALERT : Bragar Eagel & Squire, P.C. is Investigating Exicure, Inc. on Behalf of Ex..
BU
11/22Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress
AQ
11/20Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investi..
BU
11/19INVESTOR ALERT : Law Offices of Howard G. Smith Continues Its Investigation of Exicure, In..
BU
11/19EXICURE : Reports Third Quarter 2021 Financial Results and Corporate Progress - Form 8-K
PU
11/19EXICURE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/19Exicure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/19Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress
BU
More news
Analyst Recommendations on EXICURE, INC.
More recommendations
Financials (USD)
Sales 2021 0,90 M - -
Net income 2021 -49,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,66x
Yield 2021 -
Capitalization 40,6 M 40,6 M -
Capi. / Sales 2021 45,1x
Capi. / Sales 2022 4,61x
Nbr of Employees 77
Free-Float 76,4%
Chart EXICURE, INC.
Duration : Period :
Exicure, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXICURE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,46 $
Average target price 5,56 $
Spread / Average Target 1 108%
EPS Revisions
Managers and Directors
David A. Giljohann Chief Executive Officer, Secretary & Director
Brian C. Bock Chief Financial Officer
Timothy P. Walbert Chairman
Douglas E. Feltner Chief Medical Officer
Matthias G. Schroff Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EXICURE, INC.-73.98%41
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
VERTEX PHARMACEUTICALS-12.58%52 531